Abstract
In the management of metastatic prostate cancer, treatment with androgen deprivation therapy, initially with surgery via bilateral orchidectomy and more recently with medical therapy using gonadotropin-releasing hormone (GnRH) agonists, has remained the key treatment approaches for this disease stage. Notably, patients express a preference towards a medical therapy approach. We present the case study of a patient with symptomatic metastatic prostate cancer treated with the new GnRH antagonist degarelix.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have